Summary 12.4 Gene Therapy - Microbiology | OpenStax openstax.org
3,539 words - html page - View html page
One Line
Gene therapy is a potentially effective treatment for genetic abnormalities, but it carries risks such as immune responses, infections, and gene inactivation, highlighting the need for strict regulations and ethical considerations.
Slides
Slide Presentation (7 slides)
Key Points
- Gene therapy is a clinical application of genetic engineering that aims to correct genetic abnormalities by introducing nonmutated, functional genes into a patient's genome.
- Viral vectors, such as adenovirus, are often used to deliver the functional genes.
- Gene therapy has shown limited effectiveness so far, with some successful treatments for genetic diseases like cystic fibrosis and adenosine deaminase deficiency.
- Gene therapy carries risks, including triggering an inflammatory response, infection of unintended cells, reversion to an infectious state, unintentional inactivation of important genes, and potential tumor formation.
- Gene therapy clinical trials are tightly regulated by multiple federal agencies to ensure patient safety, including the FDA, OHRP, and RAC. Ethical concerns arise regarding the limits of gene therapy, including which genetic traits should be corrected, the use of gene therapy for cosmetic or enhancement purposes, and the potential for social inequality. Germ-line gene therapy raises additional ethical concerns due to its heritability and the inability of unborn individuals to provide informed consent.
Summaries
21 word summary
Gene therapy corrects genetic abnormalities, but risks include immune responses, infections, and gene inactivation. Regulations and ethics are important for oversight.
73 word summary
Gene therapy corrects genetic abnormalities by introducing functional genes, but its effectiveness is limited and risks include immune responses, infections, and inactivation of important genes. Informed consent is crucial. Clinical trials are regulated, but some argue that regulations hinder progress. Ethical concerns arise regarding therapy limits, genetic manipulation, and germ-line gene therapy. The U.S. government does not fund germ-line gene therapy research. Oversight, regulation, and balancing benefits with risks and ethics are important.
144 word summary
Gene therapy aims to correct genetic abnormalities by introducing functional genes into a patient's genome. However, it is still experimental and has limited effectiveness. Risks include immune responses, unintended infections, and inactivation of important genes. Informed consent is crucial. Clinical trials are regulated by federal agencies, although some argue that these regulations hinder progress. Ethical concerns arise regarding the limits of therapy and genetic manipulation. Questions about which traits are worthy of correction, cosmetic uses, and enhancing abilities are raised. Germ-line gene therapy raises unique ethical concerns due to heritable changes and consent issues. The U.S. government does not fund research on this type of therapy. The approval process involves financial investment and potential conflicts of interest. Data from animal trials and FDA approval are necessary. Gene therapy offers hope but carries risks. Oversight, regulation, and balancing benefits with risks and ethics are important.
350 word summary
Gene therapy is a clinical application of genetic engineering that aims to correct genetic abnormalities by introducing a nonmutated, functional gene into the patient's genome. While it holds promise as a potential cure for genetic diseases, gene therapy is still largely experimental and has shown limited effectiveness so far. There are significant risks associated with gene therapy, including immune responses to viral vectors, unintended cell infections, and the unintentional inactivation of important genes. Informed consent from patients undergoing gene therapy is crucial.
Gene therapy clinical trials are subject to extensive oversight and regulation by federal agencies such as the FDA, OHRP, and RAC at the NIH, as well as local agencies and institutional review boards. However, some argue that these regulations hinder progress in gene therapy research.
Ethical concerns surround gene therapy, particularly regarding the limits of therapy and the potential for genetic manipulation beyond treating genetic diseases. Questions arise about which genetic traits are worthy of correction and whether gene therapy should be used for cosmetic purposes or to enhance human abilities. Manipulating reproductive cells in germ-line gene therapy raises unique ethical concerns, as it could lead to heritable changes and raises questions about consent and trait modification. Currently, the U.S. government does not fund research on germ-line gene therapy in humans.
The approval process for new gene therapies involves significant financial investment and potential conflicts of interest. Researchers must collect data from animal trials and submit an IND application to the FDA. Clinical trials with human subjects can then proceed, and data on effectiveness and safety are collected. Once a therapy meets FDA standards, a New Drug Application is submitted. Conflicts of interest can arise due to the financial stakes involved in bringing a therapy to market, potentially compromising objective judgment.
In conclusion, gene therapy offers hope for treating genetic diseases but carries significant risks. Extensive oversight and regulation are in place to ensure patient safety. Ethical concerns encompass the limits of therapy, genetic manipulation, and the consequences of germ-line gene therapy. Balancing the potential benefits of gene therapy with the associated risks and ethical considerations is crucial.
516 word summary
Gene therapy is a clinical application of genetic engineering that aims to correct genetic abnormalities by introducing a nonmutated, functional gene into the patient's genome. The goal is to provide a cure for diseases caused by genetic mutations. However, gene therapy is still largely experimental and has shown limited effectiveness so far. While some treatments for genetic diseases have shown promise, there are significant risks associated with gene therapy.
One of the main risks of gene therapy is the potential for an immune response to the viral vectors used to introduce the functional gene. In some cases, this immune response can lead to organ failure. Additionally, the viral vectors may infect unintended cells, causing damage and potentially leading to illnesses such as cancer. There is also a risk that the inserted gene could unintentionally inactivate another important gene, disrupting normal cell function and potentially leading to tumor formation and cancer. These risks highlight the need for informed consent from patients undergoing gene therapy.
Gene therapy clinical trials are subject to extensive oversight and regulation. The FDA, OHRP, and RAC at the NIH are the federal agencies responsible for regulating gene therapy. They work in conjunction with local agencies and institutional review boards to ensure patient safety during clinical trials. However, some researchers argue that these regulations hinder progress in gene therapy research.
Ethical concerns surround gene therapy, particularly in regards to the limits of therapy and the potential for genetic manipulation beyond treating genetic diseases. Questions arise about which genetic traits are worthy of correction and whether gene therapy should be used for cosmetic purposes or to enhance human abilities. There are also concerns about using gene therapy to manipulate reproductive cells, which could have unintended consequences for future generations. Informed consent and the prevention of social inequality are additional ethical considerations.
Germ-line gene therapy, which involves manipulating reproductive cells, raises unique ethical concerns. While current gene therapies target non-reproductive cells, germ-line gene therapy could lead to heritable changes. This raises questions about the traits that should be modified and the ability of unborn individuals to provide consent. Currently, the U.S. government does not fund research on germ-line gene therapy in humans.
The approval process for new gene therapies involves significant financial investment and potential conflicts of interest. Researchers must collect data from animal trials and submit an IND application to the FDA. Clinical trials involving human subjects can then begin, and data on effectiveness and safety are collected. Once a therapy meets FDA standards, a New Drug Application is submitted. However, conflicts of interest can arise due to the financial stakes involved in bringing a therapy to market, potentially compromising objective judgment.
In conclusion, gene therapy holds promise as a potential cure for genetic diseases, but it also carries significant risks. The field is subject to extensive oversight and regulation to ensure patient safety. Ethical concerns surrounding gene therapy include the limits of therapy, the manipulation of genetic traits, and the potential consequences of germ-line gene therapy. It is important to balance the potential benefits of gene therapy with the risks and ethical considerations involved.